

CONSTANCE A. MORELLA

8TH DISTRICT, MARYLAND

COMMITTEE ON SCIENCE
SUBCOMMITTEE ON BASIC RESEARCH

CHAIR,
SUBCOMMITTEE ON TECHNOLOGY

COMMITTEE ON GOVERNMENT
REFORM AND OVERSIGHT
SUBCOMMITTEE ON CIVIL SERVICE

VICE CHAIR,
SUBCOMMITTEE ON THE DISTRICT OF COLUMBIA



Congress of the United States
House of Representatives

October 13, 1998

2228 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515
(202) 225-5341
FAX: (202) 225-1389

EMAIL: rep.morella@mail.house.gov

51 MONROE STREET
SUITE 507
ROCKVILLE, MD 20850
(301) 424-3501
FAX: (301) 424-5992

Dr. Shirley Ann Jackson, Chair
U.S. Nuclear Regulatory Commission
Washington, D.C. 20555


Dear Dr. Jackson:

Several of my constituents have written me expressing their concerns relating to issues the Nuclear Regulatory Commission may consider during upcoming hearings on October 21 and 22, relating to the treatment with Iodine-131 for some patients with hyperthyroidism and most patients with thyroid cancer.

Specifically, they are concerned that the NRC's consideration of a proposal to increase the number of training and experience hours from 80 to 120 for treatment of hyperthyroidism and thyroid carcinoma may have the unintended effect of discouraging endocrinologists from providing this form of treatment. I am enclosing one such letter for your consideration.

I hope you and the other Commissioners will carefully consider their concerns at the hearings and as you develop the final regulations.

Sincerely,


Constance A. Morella
Member of Congress

CAM:jrd

enclosure